Why Musk Might Influence Trump’s AI Plans

In today's email

• Hollywood De-Ages Tom Hanks with Generative AI

• AI Startup Perplexity to Triple Valuation

• OpenAI Secures Chat.com

• The Gap Between Open and Closed AI Models

• Trump’s “Light-Touch” AI Policy

• Two Established AI Investments

• New Rules for Cancer Treatment

_{Read Time: 3.5 minutes}

Quick News 

Hollywood De-Ages Tom Hanks with Generative AI in $50 Million Blockbuster: In a bold cinematic experiment, the upcoming movie Here employed generative AI to "de-age" Tom Hanks, pushing the boundaries of Hollywood’s reliance on AI. Developed by Metaphysic, the technology operates in real-time, avoiding post-production edits. (Read more)

AI Startup Perplexity to Triple Valuation to $9 Billion: Perplexity, an AI search company, is raising $500 million in its fourth funding round this year, tripling its valuation to $9 billion. This significant investment underscores the growing importance and value of AI-driven search technologies in the market. (Read more)

OpenAI Secures Chat.com in Major Domain Deal: OpenAI has acquired the premium domain name chat.com from HubSpot founder Dharmesh Shah, who reportedly purchased it in 2023 for $15.5 million. This acquisition, which redirects traffic directly to ChatGPT, hints at OpenAI's vision beyond "GPT," potentially setting the stage for broader AI applications. Shah indicated the sale involved equity in OpenAI, positioning him within one of the tech world’s fastest-growing companies. This move could reflect OpenAI's ambition to become synonymous with AI-powered communication on a global scale. (Read more)

The Gap Between Open and Closed AI Models Is Shrinking: A report by Epoch AI indicates that the discrepancy between open-source and closed AI models is narrowing. Open models, which currently lag about a year behind proprietary models like OpenAI's GPT-4, are expected to catch up with upcoming releases such as Meta's new Llama model. (Read more)

HOT TAKE
Well, it seems the White House is getting a familiar tenant.

With Donald Trump back in office, the AI landscape is poised for some intriguing shifts. Let's unpack what this means for the future of artificial intelligence.

Here’s what we might see:

• Rolling Back Biden’s AI Executive Order: The RNC platform has committed to dismantling Biden’s recent AI guidelines on Day 1, allowing industry-led safety standards to fill the gap. Trump’s team seems to prefer refining existing laws rather than creating new regulations, leaving room for states to step in.

• Military “Manhattan Project” for AI: Trump plans a defense-centric AI “Manhattan Project,” focused on military applications and fueled by collaboration with contractors like Anduril and Palantir, aiming to make the U.S. competitive with China in defense tech.

• Energy Deregulation for AI Growth: To support data center expansion and the vast energy needs of AI, Trump is considering rolling back energy infrastructure rules – an immediate boon for the data-heavy AI sector.

• Trade and Export Controls on China: Expect tighter export restrictions and scrutiny over AI tech access, particularly cloud-based tools, to curb China’s AI capabilities. This protectionist stance could hinder U.S.-China cooperation in AI but could also bolster domestic innovation.

• Elon Musk’s Influence: As a vocal advocate and informal advisor, Musk may push Trump to balance innovation with selective oversight, especially around high-stakes AI risks. His influence could add a dose of caution to Trump’s otherwise “light-touch” approach.

Trump’s policies could bring faster deployment and less red tape, giving U.S. companies a competitive edge and easing costs tied to regulatory compliance. 

However, there’s a trade-off – less federal oversight may lead to inconsistent standards across states, and some in the industry worry that competition with China could restrict access to global markets and talent.

The bottom line? Trump’s AI agenda and his “Light-Touch” policy might fast-track innovation, but businesses will need to self-regulate wisely to avoid bumps on the road to progress.

Together with Convergence AI

Proxy, the AI Agent for Everyday Life

Imagine if you had a digital clone to do your tasks for you. Well, meet Proxy…

Last week, Convergence, the London based AI start-up revealed Proxy to the world, the first general AI Agent.

Users are asking things like “Book my trip to Paris and find a restaurant suitable for an interview” or “Order a grocery delivery for me with a custom weekly meal plan”.

You can train it how you choose, so all Proxy’s are different, and personalised to how you teach it. The more you teach it, the more it learns about your personal work flows and begins to automate them.

Join the waitlist here

The Magic Vault

AI is a generational investment, but you don’t need risky stocks to benefit.

Two established companies we talk about all the time – AMD and Microsoft – are primed for AI-driven growth. Here’s how:

• AMD: Key supplier of GPUs for AI training, with data center revenue doubling year-over-year. Recent acquisitions and strong demand in data centers could drive a 52% earnings increase in 2025.

• Microsoft: Integrating AI across Microsoft 365 and Azure cloud services, Microsoft is embedding AI for consumers and businesses alike. Its growth in AI and cloud could drive steady stock gains.

For those seeking stable AI investments, AMD and Microsoft offer solid growth without high risk, underscoring how established tech giants are leading the charge.

Both companies are well-positioned to capitalize on AI’s rise, making them top choices for future-focused portfolios.

More About AI Around the Globe

AI-powered spatial biomarkers are rewriting the rules for cancer treatment

At the SITC 2024, Nucleai revealed groundbreaking advances in AI-driven spatial biomarker analysis for immunotherapy in lung and skin cancer. The company showcased how their AI platform improves treatment precision by mapping cellular arrangements to reveal treatment resistance and patient response predictions.

• Non-Small Cell Lung Cancer (NSCLC): Nucleai’s platform identified unique immune and metabolic biomarkers, helping doctors predict which patients may respond well to combination therapies.

• Melanoma: Using Bio-Techne's COMET platform, Nucleai analyzed spatial proteomic profiles to optimize immunotherapy strategies, offering new tools for more personalized treatments.

These advancements are a game-changer for clinical research, accelerating the development of precision therapies that are customized to individual patients’ biology. For the AI industry, this illustrates the technology’s potential to provide high-impact, data-driven insights that can transform complex areas of healthcare.

AI-driven spatial biomarker analysis could soon become a standard for clinical trials, enhancing patient outcomes and potentially reshaping the oncology treatment landscape.

Let's Chat About AI

This is all for today!

Replay to this email with your thoughts.

AI is more than just a buzzword. It’s a shift in how we live and work. And understanding it a bit better means you can make smarter choices about the tech you use every day.

_FEEDBACK